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Abstract
Optimal staging and evaluation of residual lesions of invasive fungal infections (IFIs) are major challenges in the immunocompromised
host. Preliminary data have suggested that [18F]ﬂuorodeoxyglucose ([18F]FDG) uptake may be observed in the course of active inva-
sive fungal infections. The aim of this study was to assess the role of positron emission tomography with [18F]FDG ([18F]FDG-PET)
in the diagnosis and staging of IFI. A prospective monocentric study evaluating [18F]FDG-PET in 30 consecutive adults and children
with European Organization for Research and Treatment of Cancer/Mycoses Study Group probable or proven IFI was performed.
Twenty males and ten females (median age, 45 years (range 6–75 years)) were enrolled. Twenty-six were immunocompromised, as
follows: haematological malignancy (18) with allogeneic stem cell transplantation (16/18), solid tumour (three), solid organ transplanta-
tion (two), diabetes mellitus (two) and cystic ﬁbrosis (one). IFIs were acute invasive aspergillosis (ten), chronic disseminated candidia-
sis (ten), zygomycosis (two), black grains eumycetoma (two), pulmonary Histoplasma capsulatum var. capsulatum histoplasmosis (two),
and Phomopsis sp. osteoarthritis, Scedosporium apiospermum and Candida krusei spondylodiscitis, and acute pulmonary coccidioidomyco-
sis in one case each. An increased uptake of [18F]FDG was observed in all areas previously identiﬁed by computed tomography and/
or magnetic resonance imaging to be involved by IFI. In 4/10 chronic disseminated candidiasis cases, [18F]FDG-PET revealed small
splenic abscesses that were unapparent on the corresponding computed tomography scan. [18F]FDG uptake disappeared after
6 months of antifungal therapy in three patients with chronic disseminated candidiasis for whom the [18F]FDG-PET was performed
to assess the evolution of the disease. [18F]FDG-PET could potentially be useful for the initial diagnosis and staging of IFI. Whether
or not [18F]FDG-PET might be useful for assessing the optimal duration of IFI therapy should now be assessed in a speciﬁc prospec-
tive study.
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Introduction
Invasive fungal infections (IFIs) represent major diagnostic and
therapeutic challenges in immunocompromised patients, espe-
cially those with haematological malignancy, for whom diagno-
sis and antifungal treatment are often delayed because of a
lack of speciﬁc clinical and radiological features [1]. At pres-
ent, the diagnosis of IFI relies on sophisticated microbiological
tools, including culture and molecular identiﬁcation [2,3],
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whereas radiological investigations are still mostly based on
conventional computed tomography (CT) [4]. Although pul-
monary CT has demonstrated its value for the early diagnosis
of invasive pulmonary aspergillosis [5,6], it may miss other
foci of infections. In addition, appropriate evaluation of the
residual infection has now become a new challenge in immu-
nocompromised patients surviving their initial episode of IFI.
In these patients, appropriate duration of antifungal therapy is
a key issue for optimal timing of the subsequent speciﬁc man-
agement of the underlying disease. Preliminary investigations
have suggested that classical isotopic methods such as gal-
lium-67 scintigraphy and leukocyte scintigraphy could be use-
ful for the diagnosis of IFI, but so far there is no consensus
regarding their use in clinical practice [7].
[18F]2-Fluoro-2-deoxy-D-glucose ([18F]FDG) accumulates
in metabolically active cells, including neoplastic and inﬂam-
matory cells, and produces a distinct image during positron
emission tomography (PET) scanning ([18F]FDG-PET). It is
thus useful for detecting malignant and inﬂammatory pro-
cesses [8,9]. Similarly, the contribution of [18F]FDG-PET in
the diagnosis of infectious diseases will probably be recog-
nized and better codiﬁed in the future. Indeed, several
groups have demonstrated its contribution in the assessment
of osteomyelitis, infected prosthetic devices, fever of
unknown origin, and AIDS. Whether or not [18F]FDG-PET
represents a useful diagnostic tool during IFI remains
unknown. Furthermore, for fungal lesions involving subcuta-
neous tissues or bones, conventional methods may not be
sensitive enough. Finally, [18F]FDG uptake may also consti-
tute a potential marker of residual IFI, which would be par-
ticularly useful in helping to reduce the duration of costly
systemic antifungal therapies with their inherent side effects
in severely immunocompromised hosts.
We thus prospectively assessed the contribution of
[18F]FDG-PET in the diagnosis and staging of proven IFI in a
monocentric cohort of 30 consecutive patients.
Patients and Methods
Patients
From among 53 patients who presented with IFI during the
study period, we selected 30 consecutive patients who were
naı¨ve to antifungals. These 30 consecutive patients, 29 adults
and one child hospitalized at the Centre d’Infectiologie
Necker-Pasteur, Paris for the diagnosis or management of
IFI, were prospectively evaluated with [18F]FDG-PET
between November 2005 and October 2006. All patients
underwent exhaustive, clinical, radiological and microbiologi-
cal work-ups, and all (or their parents) gave their informed
consent to participate. All patients fulﬁlled the 2002
European Organization for Research and Treatment of
Cancer/Mycoses Study Group diagnostic criteria for proven
or probable IFI [10]. Exclusion criteria included: (i) any other
infection (e.g. bacterial pneumonia or osteomyelitis; (ii) con-
siderable comorbid medical, surgical or psychiatric conditions
that were currently uncontrolled or that may have interfered
with completion of the study; and (iii) inability to tolerate
staying in a PET scanner for the duration of the examination.
Diagnostic work-up for IFI
Conventional diagnostic tests for IFI were routinely per-
formed in all patients prior to the time of [18F]FDG-PET, and
included routine laboratory tests (blood cell count, chemistry,
C-reactive protein, microbial cultures – blood, urine, sputum,
and others as clinically indicated), twice-weekly sequential
monitoring of galactomannan in severely neutropenic patients,
chest radiography or CT, and magnetic resonance imaging
(MRI) when appropriate. The same qualiﬁed radiologist (SP)
performed all radiological procedures. Additional diagnostic
tests, such abdominal CT, bronchoalveolar lavage, endoscopy
and/or tissue biopsy, were performed as clinically indicated.
CT was used to evaluate all cases of invasive aspergillosis or
chronic disseminated candidiasis before the [18F]FDG-PET.
CT was performed very early after the suspicion of IFI.
[18F]FDG-PET and CT always were performed within 48 h
following the initiation of antifungal therapy.
All CT scans were obtained with a four-section CT scanner
(MX8000; Philips Medical Systems). CT was performed in 11
patients with 5-mm collimation through the thorax, abdomen
and pelvis, and in three patients through the abdomen and
pelvis, and included contrast enhancement in all cases. Contig-
uous 5-mm-thick sections of the entire chest were obtained
in nine patients without injection of contrast medium. High-
resolution 1-mm-thick images were also obtained in this
group of patients. CT scans of the paranasal sinus were
obtained in ﬁve patients with 3-mm collimation extending
from the top of the frontal sinuses down to the maxillary alve-
olus, without contrast material administration. Four patients
underwent MRI, especially for bone infection and spondylitis
imaging, with a 1.5-T MRI unit (Signa; GE Medical Systems).
T1-weighted and T2-weighted images were obtained, includ-
ing contrast material enhancement. Lower limbs were
explored in two patients, and the spine also in two patients.
For the diabetic patients, the blood sugar was controlled with
either oral hypoglycaemic agents or insulin before scanning.
[18F]FDG-PET imaging
Every patient fasted for a minimum of 6 h before the intrave-
nous injection of 5 MBq/kg of [18F]FDG. Whole body imaging
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was performed on a PET-CT Philips Gemini 16, in accor-
dance with the manufacturer’s guidelines, beginning 45–
60 min following tracer injection. The [18F]FDG was injected
via intravenous catheter. PET acquisition parameters were as
follows: whole body scanning from the vertex to the hips,
3 min per step, with no contrast enhancement CT (140 kV,
120 mA to 160 mA, depending on the patient’s weight,
2-mm slices, pitch 1.5), and from the hips to the feet (2 min
per step), with CT only when clinically required, in order to
minimize the dose–length product. Emission data were itera-
tively reconstructed using a dedicated full three-dimensional
row-action maximization-likelihood algorithm, delivered with
the [18F]FDG-PET systems by the manufacturer, computing
non-corrected and attenuation-corrected data (for segments
with corresponding CT slices). Images were analysed on a
Brilliance device (Philips), simultaneously displaying non-cor-
rected, attenuation-corrected and CT data.
Image analysis
All PET/CT scans were reviewed by two experienced
nuclear medicine physicians (CM and MF), who were not
aware of the patient’s clinical history and ﬁnal IFI diagnosis.
Images were visually interpreted as normal, equivocal or with
pathological uptake, according to standard uptake values
(respectively, below 2, between 2 and 3 and above 3 on
attenuation-corrected data, or to uptake above lung or soft
tissue physiological uptake on non-corrected data).
Results
No adverse effect was observed after injection of the isotope
in the 30 patients who were evaluated by [18F]FDG-PET.
Demographic and clinical data are summarized in Table 1.
Demographic and clinical descriptions
Thirty patients (20 males and ten females) were consecu-
tively recruited during the study period. Their median age
was 45 years (range: 6–75 years). Eighteen had a haemato-
logical malignancy, including 16 with allogeneic stem cell
transplantation (eight of whom were grafted with cells from
a matched, unrelated donor). Ten of the latter patients
received major immunosuppressive therapy for chronic graft-
versus-host disease at the time of IFI diagnosis. Eight patients
had recently received antineoplastic chemotherapy, and 15
patients high-dose steroid therapy. Among the four immuno-
competent patients, one had cystic ﬁbrosis and three had no
past medical history. Eight patients had recently experienced
profound neutropenia, ﬁve of whom were still neutropenic
(<500/mm3) at the time of initial [18F]FDG-PET. IFIs were
associated with moulds in 14 cases: eight deﬁnite and two
probable cases of invasive aspergillosis (isolated pulmonary in
four cases, pulmonary and sinus in four cases, sinus and brain
in one case, and isolated liver aspergillosis in one case), two
cases of zygomycosis, and one case each of Scedosporium
apiospermum spondylitis and Phomopsis sp. osteoarthritis.
Yeast infections included chronic disseminated candidiasis
(ten) (ﬁve deﬁnite and ﬁve probable) and one case of Candida
krusei vertebral osteomyelitis. In three cases, [18F]FDG-PET
was performed for the evaluation of endemic dimorphic IFI,
including two cases of lung Histoplasma capsulatum var. cap-
sulatum histoplasmosis and one acute pulmonary coccidioido-
mycosis. In two cases, [18F]FDG-PET was performed during
the course of black grains eumycetoma: one was related to
Madurella spp., and the other to Leptospheria senegalensis.
[18F]FDG-PET for initial staging of IFI
In all patients, [18F]FDG-PET revealed [18F]FDG uptake in
the area(s) previously identiﬁed by conventional CT scan or
MRI as being involved by the IFI. All [18F]FDG-PET scans
were performed within 48 h following the initiation of anti-
fungal therapy, in order to avoid false-negative results.
Invasive mould infections. A 6-year-old boy with chronic gran-
ulomatous disease was diagnosed with probable invasive pul-
monary aspergillosis. [18F]FDG-PET revealed tracer uptake in
the area corresponding to the lesions indentiﬁed on the cor-
responding chest CT scan (Fig. 1a,b).
A 33-year-old patient with a past history of refractory
Hodgkin’s disease was admitted for fever of unknown origin.
Three months earlier, he underwent allogeneic stem cell
transplantation. He was diagnosed with chronic graft-versus-
host disease requiring immunosuppression with cyclosporine
and prednisone. He did not receive antifungal prophylaxis,
and remained neutropenic. Three months post-transplanta-
tion, he was admitted for investigation of probable pulmo-
nary invasive aspergillosis, on the basis of two consecutive
positive serum galactomannan detections. [18F]FDG-PET
revealed tracer uptake in the right upper lobe (Fig. 1c). His-
tological study revealed both invasive aspergillosis and Hodg-
kin’s disease relapse.
Yeast infections. Ten patients with chronic disseminated can-
didiasis were evaluated in our study. In six of them,
[18F]FDG-PET revealed lesions undetected by CT scan.
A 27-year-old male patient with testicular cancer presented
with multiple hypodense nodular lesions in the liver and the
spleen consistent with chronic disseminated candidiasis, occur-
ring during haematopoietic recovery. Although blood cultures
were negative for Candida spp., the CT-guided liver biopsy
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TABLE 1. Major characteristics of 30 patients with invasive fungal infections who underwent [18F]2-ﬂuoro-2-deoxy-D-glucose
([18F]FDG) positron emission tomography (PET) imaging
Patient
Age
(years) Sex Underlying disease
Invasive fungal infection and
diagnostic modalities Initial CT ﬁndings Initial PET ﬁndings
Follow-up PET
ﬁndings
1 46 M Liver transplantation
Steroids
Deﬁnite liver aspergillosis Three nodular lesions [18F]FDG uptake in the liver
with three nodular lesions
No
2 48 F Lymphoma
Steroids,
chemotherapy,
R-CHOP
Probable invasive pulmonary
aspergillosis
Lesion in the right
upper lobe
[18F]FDG uptake in the right
upper lobe
No
3 69 M Hairy cell leukaemia
Cladribine, steroids
Deﬁnite invasive pulmonary and
sinus aspergillosis
Lesion in the left
upper lobe
[18F]FDG uptake in the left
upper lobe
No
4 39 F Acute myeloid
leukaemia
Allogeneic HSCT,
GVHD
Deﬁnite pulmonary and sinus
aspergillosis
No lesion [18F]FDG uptake in the left
lower lobe
No
5 33 M Relapsing Hodgkin’s
disease
Allogeneic HSCT,
steroids
Deﬁnite invasive pulmonary
aspergillosis
Lesion in the right
upper lobe
[18F]FDG uptake in the right
upper lobe
Yes, decrease
in [18F]FDG
uptake
6 65 M AIDS
HAART
Kaposi sarcoma
COPD
Deﬁnite invasive sinus and
pulmonary aspergillosis
No lesion seen in the
chest CT scan
[18F]FDG uptake in the right
upper lobe
No
7 56 M Kidney transplantation
Tacrolimus and
mycophenolate
mofetil, steroids
Deﬁnite invasive pulmonary
aspergillosis
Nodular lesion in the
left lower lobe
[18F]FDG uptake in the left
lower lobe
No
8 68 M Diabetes mellitus Deﬁnite sinus and cerebral
invasive aspergillosis
Nodular lesion in the
left lower lobe
[18F]FDG uptake in the left
lower lobe
No
9 6 M Chronic
granulomatous
disease
Interferon-c therapy
Probable invasive pulmonary
aspergillosis
Nodular lesion in the
right upper lobe
[18F]FDG uptake in the right
upper lobe
Yes, persistent
uptake of
[18F]FDG
10 75 F Giant cell arteritis
Steroids
Deﬁnite sinus and pulmonary
invasive aspergillosis
No lesion [18F]FDG uptake in the right
upper lobe
No
11 22 M Relapsing acute
leukaemia
Allogeneic HSCT,
GVHD, steroids
Deﬁnite hepatosplenic candidiasis Six nodular lesions
seen on the CT
scan
[18F]FDG uptake in the liver
with six nodular lesions
No
12 56 M Chronic lymphoid
leukaemia
Steroids,
alemtuzumab
Deﬁnite hepatosplenic candidiasis Four nodular lesions
in the same area of
the liver
[18F]FDG uptake in the liver
with ﬁve nodular lesions
No
13 48 F Chronic myeloid
leukaemia
Steroids, allogeneic
HSCT
Deﬁnite hepatosplenic candidiasis One nodular lesion
seen on the liver on
the CT scan
[18F]FDG uptake in the liver
with four nodular lesions
No
14 27 M Testicular cancer
Antineoplastic
chemotherapy,
steroids
Probable hepatosplenic
candidiasis
Eight lesions seen in
the spleen on the
CT scan
[18F]FDG uptake in the spleen
with ten lesions
Yes, decrease
in [18F]FDG
uptake
15 24 M Hodgkin’s disease
Allogeneic HSCT,
steroids, GVHD
Deﬁnite hepatosplenic candidiasis Five lesions seen in
the liver on the CT
scan and
echography
[18F]FDG uptake in the liver
and spleen with seven lesions
Yes, persistence of
[18F]FDG uptake
at 6 and 9 months
16 54 F Acute leukaemia
Antineoplastic
chemotherapy
Deﬁnite hepatosplenic candidiasis No lesion seen in the
spleen CT
[18F]FDG in the liver and the
spleen
No
17 48 F Acute leukaemia
Antineoplastic
chemotherapy
Probable hepatosplenic
candidiasis
Three nodular lesions
seen in the liver and
one in the spleen
[18F]FDG uptake in the liver
and spleen, three nodular
lesions in the liver and two
in the spleen
No
18 49 M Hodgkin’s disease
relapsed
HIV
Probable hepatosplenic
candidiasis
Lesions seen in liver
and spleen in the
same area of the
liver
18FDG uptake in the liver and
spleen
No
19 25 M Acute leukaemia
Chemotherapy,
allogeneic HSCT
Probable hepatosplenic
candidiasis
Lesions seen in the
liver and spleen in
the same area of
the liver
[18F]FDG uptake in the liver
and spleen
No
20 34 M Acute leukaemia
Chemotherapy
Probable hepatosplenic
candidiasis
Lesions seen in the
liver and spleen
[18F]FDG uptake in the liver
and spleen
No
21 46 F Acute myeloid
leukaemia
Allogeneic HSCT,
GVHD
Deﬁnite pulmonary
histoplasmosis
Pulmonary inﬁltrates [18F]FDG uptake in both lungs No
22 46 F Uterus cancer, past
history of lung
histoplasmosis
Positive serology, asymptomatic
pulmonary nodules
Multiple nodular
lesions in both lungs
No [18F]FDG uptake No
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showed a polymorphonuclear inﬁltrate and hyphae. [18F]FDG-
PET revealed at least ten focal areas of increased uptake in the
spleen and six in the liver. It is of note that two of these lesions
were not detectable on the corresponding CT scan (Fig. 2a). A
second [18F]FDG-PET scan was performed 3 months after the
ﬁrst, and showed no uptake (Fig. 2b).
Dimorphic fungal infections. Three patients were evaluated
for initial staging of dimorphic fungal infections. Two of them
were followed for histoplasmosis and one of them for acute
pulmonary coccidioidomycosis.
A 60-year-old female developed acute pulmonary coccidi-
oidomycosis after returning from a 5-week vacation in Irvine,
CA, USA. Chest X-ray and CT scanning revealed inﬁltrates
in the upper left lobe. Bronchoalveolar lavage ﬂuid grew Coc-
cidioides immitis. [18F]FDG-PET revealed high uptake of
[18F]FDG in the left upper lobe. In addition, it also revealed
two other foci of [18F]FDG uptake that were not detectable
on the CT scan (Fig. 3).
Fungal osteomyelitis. Five patients with musculoskeletal fungal
infections were enrolled in this study.
A 56-year-old West African man was admitted for a pain-
less leg ulcer with osteomyelitis. A deep subcutaneous biopsy
sample grew Phomopsis sp., and [18F]FDG-PET showed
uptake in the left ankle (Fig. 4a). The MRI scan had shown
the same.
A 55-year-old West African man was admitted for the
evaluation and treatment of Madurella spp. mycetoma of the
left foot (Fig. 4b).
Evaluation of residual IFI with [18F]FDG-PET
[18F]FDG-PET was performed to assess residual IFI in eight
cases. In four cases of invasive aspergillosis, uptake of
[18F]FDG either decreased or disappeared 4 months after
the beginning of antifungal therapy (data not shown). For
two patients with chronic disseminated candidiasis, lesions
disappeared at 3 and 16 months after antifungal therapy initi-
ation, respectively (sequential follow-up of one representa-
tive patient is presented in Fig. 2. These observations, in
combination with the normalization of clinical status and
biological test results, led us to stop the antifungal therapy,
and allowed a new antineoplastic chemotherapy course to
be started.
In the last patients, [18F]FDG-PET was performed to
assess the evolution of disease identiﬁed by conventional
tools (Fig. 3b). For instance, a 46-year-old female with a
past history of lung histoplasmosis was admitted for evalua-
tion of pulmonary nodules revealed by chest CT while she
was receiving chemotherapy and radiotherapy for uterine
carcinoma. [18F]FDG-PET was performed and did not show
any uptake in the lungs, thereby conﬁrming inactive nodular
lesions rather than active infection or malignancy (data not
shown).
TABLE 1. (Continued)
Patient
Age
(years) Sex Underlying disease
Invasive fungal infection
and diagnostic modalities Initial CT ﬁndings Initial PET ﬁndings
Follow-up PET
ﬁndings
23 61 F No underlying disease Acute pulmonary
coccidioidomycosis
Nodular lesion in the
right upper lobe,
mediastinal
adenopathy
[18F]FDG uptake in the
mediastinum and right upper
lobe
Yes, decrease
in [18F]FDG
uptake
24 42 M No, African man Mycetoma, Leptospheria
senegalensis
Osteoarthritis of the
lower limb seen on
technetium bone
scan
[18F]FDG uptake in the right
lower limb and right ﬁbula
Yes, decrease
in [18F]FDG
uptake
25 55 M No, African man Mycetoma, Madurella spp. Osteoarthritis of the
lower limb seen on
technetium bone
scan
[18F]FDG uptake in the left
lower limb and right tibia
No
26 59 M Diabetes mellitus
African man
Phomopsis sp. osteoarthritis Osteoarthritis seen
on technetium bone
scan
18FDG uptake in the ankle and
tibia
Yes, decrease
of the FDG
uptake
27 32 M Cystic ﬁbrosis,
chronic liver disease
Deﬁnite Scedosporium
apiospermum spondylitis
High-intensity signal in
T10, T11 and T12
on MRI, but not in
L2 and L3
[18F]FDG uptake in T10, T11,
T12, L2, and L3
Yes, persistence
of [18F]FDG
uptake, despite
antifungal therapy
28 58 F Non-Hodgkin’s
malignant
lymphoma,
rheumatoid arthritis
Probable sinus and pulmonary
zygomycosis
Lung inﬁltrates,
sinusitis
No [18F]FDG uptake in the
sinus area, [18F]FDG uptake
in the lungs
No
29 59 F Diabetes mellitus Deﬁnite sinus and pulmonary
zygomycosis
Multiple nodular
lesions in both lungs
[18F]FDG uptake in both lungs
and in the mediastinum
No
30 70 M Chronic lymphoid
leukaemia
Deﬁnite Candida krusei
spondylodiscitis
Spondylodiscitis seen
in L3 on MRI
[18F]FDG uptake in the L3
spine
No
COPD, chronic obstructive pulmonary disease; CT, computed tomography; F, female; GVHD, graft-versus-host disease; HAART, highly active antiretroviral therapy; HIV,
human immunodeﬁciency virus; HSCT, haematopoietic stem cell transplantation; M, male; MRI, magnetic resonance imaging; R-CHOP, rituximab + cyclophosphamide +
doxorubicin + viucristine + preduisone.
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In these eight cases, [18F]FDG-PET was performed every
3 months for 1 year, and for two patients, [18F]FDG-PET
was performed every 6 months for the following 2 years.
Discussion
We report here the results of the ﬁrst prospective study
evaluating [18F]FDG-PET for the initial and residual staging
of a wide range of consecutive IFIs. Our aim was to evalu-
ate this technique and address the challenges of early diag-
nosis and precise localization of IFI in both
immunocompromised [10,11] and immunocompetent
patients. Conventional imaging techniques such as CT and
MRI provide excellent structural resolution for visualizing
advanced disease [5]. However, these modalities may give
false-negative results for the detection of early disease,
especially in neutropenic patients [12,13]. Preliminary use of
[18F]FDG-PET in the oncology setting has revealed cases
of false-positive uptake corresponding to a wide range of
infections, usually opportunistic in the context of immuno-
suppression [14]. Here, we show the power of [18F]FDG-
PET to detect IFI, with at least the same sensitivity as
conventional imaging. In addition, we were also able to
detect infectious foci that had not been identiﬁed with
conventional methods.
Indeed, all areas of infection, whatever the fungal pathogen
involved, observed with conventional imaging techniques
such as MRI and CT scan were detected by [18F]FDG-PET. It
is of note that [18F]FDG-PET was able to detect infected
areas of lung, sinus as well as subcutaneous, and bone fungal
infections. These results support those obtained in prelimin-
ary studies that suggested the clinical usefulness of
[18F]FDG-PET for the diagnosis of IFIs in a limited number of
patients. Ho et al. [15] were the ﬁrst to demonstrate
[18F]FDG uptake, in four cases of lung and hepatosplenic
candidiasis. In addition, [18F]FDG uptake was observed in
invasive mould infections, involving the lung and brain [16].
Finally, one case of lung cryptococcosis was also associated
with [18F]FDG uptake [17].
(a)
(b) (c)
FIG. 1. (a) Coronal emission. Positron emis-
sion tomography (PET) with [18F]2-ﬂuoro-2-
deoxy-D-glucose ([18F]FDG-PET) shows an
inﬂammatory lesion in the right lower lobe.
Both PET and computed tomography (CT)
gave abnormal ﬁndings in the context of inva-
sive pulmonary aspergillosis. (b) Coronal emis-
sion. [18F]FDG-PET scan 3 months after bone
marrow transplant (BMT). Hypermetabolic
lesions have disappeared. (c) [18F]FDG-PET
scan shows uptake in the right upper lobe, in
accordance with what was observed on the
corresponding CT scan. The ﬁnal diagnosis
was, in fact, invasive aspergillosis and relapsing
Hodgkin’s disease.
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Importantly, [18F]FDG-PET also revealed occult foci of IFI
in ten cases, notably new foci in the liver in six cases of
chronic disseminated candidiasis, and unidentiﬁed foci of
infection in two cases of mould sinusitis. Some bone lesions,
which had been detected in the two patients with fungal
spondylitis, had not been previously detected by the conven-
tional techniques. Together, these results suggest that
[18F]FDG-PET is able to detect active functional/metabolic
changes reﬂecting inﬂammatory cell activity before the onset
of anatomical abnormalities as assessed with conventional
radiological tools. This is in line with data from Bleeker-Rov-
ers et al. [18], who described patients with invasive candidia-
sis in whom [18F]FDG-PET showed multiple foci of [18F]FDG
uptake, contrasting with the lack of abnormality detected
with conventional radiological tools.
Although the sensitivity of this new imaging procedure is
valuable for assessing various types of IFI, its speciﬁcity
remains to be determined, especially for discriminating infec-
tion from malignancy and inﬂammatory disease (e.g. in the
particular setting of chronic granulomatous disease) [7].
(a)
(b)
FIG. 2. (a) Accumulation of [18F]2-ﬂuoro-2-
deoxy-D-glucose ([18F]FDG) in the liver before
antifungal treatment in a patient with hepa-
tosplenic candidiasis. (b) Three months after
the beginning of antifungal therapy, [18F]FDG
uptake has disappeared.
(a)
(b)
FIG. 3. (a) Chest computed tomography
shows a single nodular shadow with an irregu-
lar margin, spiculation, convergence of periph-
eral vessels and pleural indentation, and
positron emission tomography with [18F]2-
ﬂuoro-2-deoxy-D-glucose ([18F]FDG) ([18F]FDG-
PET) demonstrated accumulation in the left
lower lobe and uptake in a mediastinal ade-
nopathy. (b) Three months later, [18F]FDG-
PET shows decreased uptake of [18F]FDG in
the same area. The diagnosis of coccidioido-
mycosis was conﬁrmed by bronchoalveolar
lavage, which grew Coccidioides immitis.
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Physicians should consider the potential alternative diagnosis
of IFI when discovering pulmonary or hepatic nodules or
bone lysis in the oncological setting. Even though high-inten-
sity uptake in patients with central nervous system aspergil-
losis without evidence of suggestive lesions on CT imaging
has been reported [16], we do not recommend the use of
[18F]FDG-PET in cases of cerebral IFI, as the cerebral cortex,
which uses glucose as a substrate, exhibits spontaneous high
uptake of [18F]FDG. During exploration of the thorax, it is
desirable that normal organs do not interfere with the inter-
pretation of images. Normal areas in the lungs and mediasti-
num are not problematic, but the heart may show relatively
high uptake of [18F]FDG, especially if the patients has had
meals. Indeed, myocardial glucose kinetics are related to
feeding state, insulin and free fatty acid levels, and heart
work.
Finally, regarding the decision to stop antifungal therapy
[19], our data suggest that [18F]FDG-PET might be useful for
monitoring the response to antifungal therapy, as shown in
six cases of our series. In our experience, the ﬁnding of
decreased uptake of [18F]FDG at the site of infection could
result in a shortened duration of systemic antifungal treat-
ment, without evidence of IFI relapse on subsequent follow-
up imaging studies. In the latter six patients, resolution of
the infection noted on corresponding CT or MRI was associ-
ated with scarring, and occurred several weeks after the
decrease or disappearance of [18F]FDG uptake. Furthermore,
[18F]FDG-PET providing whole body imaging, may also be a
useful tool for the assessment of the overall therapeutic
response [19]: preliminary experience in a few patients has
suggested that [18F]FDG uptake actually decreases during
antifungal therapy [16,20]. However, these results raise ques-
tions about the cause of [18F]FDG uptake in IFI. Indeed, in
some cases, the [18F]FDG-PET activity persists for a surpris-
ingly long time. This is probably linked to the inﬂammation
that may still surround non-viable fungal elements. The best
paradigm remains chronic disseminated candidiasis, in which
liver biopsy most often shows inﬂammatory cells, despite the
absence of viable yeasts, and for which uptake of [18F]FDG
may persist. This clearly suggests that uptake of [18F]FDG
reﬂects acute inﬂammation rather than microbiologically
active infection as such. We might speculate that experimen-
tal animal models could help to identify new imaging tools
for distinguishing between active infection and residual local
inﬂammation.
Finally, in these types of patient, especially immunocom-
promised hosts, an emerging question is the increased risk
of cancer. Indeed PET/CT examinations, especially those that
include diagnostic CT, result in increased patient radiation
exposure as compared with stand-alone CT or PET examina-
tions, as the effective dose is a combination of that from
PET and that from CT. Indeed, a recent study demonstrated
that whole body PET/CT scanning was accompanied by a
substantial radiation dose, with its subsequent cancer risk,
especially in young patients. The induced cancer risk was
estimated to be 5.5–20.9% higher in the Hong Kong popula-
tion than in the US population for 20-year-old individuals
[21].
In conclusion, [18F]FDG-PET constitutes a valuable and
sensitive tool for the initial staging of non-central nervous
system IFI, when compared with conventional radiological
methods. In addition, our work also suggests that
[18F]FDG-PET may be valuable for the assessment of resid-
ual IFI. The value of [18F]FDG-PET for determining the opti-
mal duration of antifungal therapy in immunocompromised
hosts with IFI now deserves investigation in a prospective
study.
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(a) (b)
FIG. 4. (a) This patient presented with [18F]2-
ﬂuoro-2-deoxy-D-glucose ([18F]FDG) uptake in
the left limb, and this accumulation was caused
by a Phomopsis sp. post-traumatic infection. (b)
Positron emission tomography with [18F]FDG
shows accumulation of the isotope in the left
foot, corresponding to a proven Madurella
foot.
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